Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACST Acasti Pharma	$3.11	$3.22	$1.98 ▼ $3.60	$29.23M	1.52	22,722 shs	12,261 shs
CNTB Connect Biopharma	$1.73 +3.6%	$1.58	$0.51 ▼ $2.86	$93.06M	-0.09	161,814 shs	96,342 shs
CRBP Corbus Pharmaceuticals	$9.70 +5.2%	$8.57	$4.64 ▼ $61.89	$112.99M	3.2	112,351 shs	89,611 shs
ZNTL Zentalis Pharmaceuticals	$1.87 +14.0%	$1.39	$1.01 ▼ $5.44	$118.30M	1.71	636,034 shs	2.62 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACST Acasti Pharma	0.00%	0.00%	0.00%	0.00%	+27.98%
CNTB Connect Biopharma	-7.73%	-29.24%	-16.50%	+102.67%	+59.05%
CRBP Corbus Pharmaceuticals	+0.99%	-3.86%	+7.71%	+22.28%	-83.90%
ZNTL Zentalis Pharmaceuticals	+3.14%	+10.07%	+17.99%	+32.26%	-47.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACST Acasti Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CNTB Connect Biopharma	3.3416 of 5 stars	3.8	5.0	0.0	0.0	2.3	2.5	0.0
CRBP Corbus Pharmaceuticals	4.2867 of 5 stars	3.6	3.0	0.0	4.7	2.8	2.5	0.0
ZNTL Zentalis Pharmaceuticals	1.7892 of 5 stars	3.3	2.0	0.0	0.0	2.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACST Acasti Pharma	3.00	Buy	$10.00	221.54% Upside
CNTB Connect Biopharma	3.50	Strong Buy	$7.00	304.62% Upside
CRBP Corbus Pharmaceuticals	3.10	Buy	$49.00	405.15% Upside
ZNTL Zentalis Pharmaceuticals	2.67	Moderate Buy	$8.20	338.50% Upside

Current Analyst Ratings Breakdown

Latest ACST, ZNTL, CNTB, and CRBP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
8/7/2025	ZNTL Zentalis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/7/2025	ZNTL Zentalis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $5.00
8/6/2025	CRBP Corbus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$56.00 ➝ $53.00
7/30/2025	CRBP Corbus Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$28.00
7/22/2025	CNTB Connect Biopharma	Northland Capmk Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/12/2025	CRBP Corbus Pharmaceuticals	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/12/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$7.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACST Acasti Pharma	N/A	N/A	N/A	N/A	$6.57 per share	N/A
CNTB Connect Biopharma	$26.03M	3.70	N/A	N/A	$1.28 per share	1.35
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	$9.06 per share	N/A
ZNTL Zentalis Pharmaceuticals	$67.43M	2.00	N/A	N/A	$3.81 per share	0.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACST Acasti Pharma	-$12.85M	-$1.44	N/A	N/A	N/A	N/A	-13.61%	-11.56%	N/A
CNTB Connect Biopharma	-$15.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/5/2025 (Estimated)
CRBP Corbus Pharmaceuticals	-$40.21M	-$4.76	N/A	N/A	N/A	N/A	-43.65%	-39.62%	11/6/2025 (Estimated)
ZNTL Zentalis Pharmaceuticals	-$165.84M	-$2.26	N/A	N/A	N/A	N/A	-51.62%	-40.28%	N/A

Latest ACST, ZNTL, CNTB, and CRBP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/5/2025	H1 2025	CNTB Connect Biopharma	-$0.22	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	ZNTL Zentalis Pharmaceuticals	-$0.56	-$0.37	+$0.19	-$0.37	N/A	N/A
8/5/2025	Q2 2025	CRBP Corbus Pharmaceuticals	-$1.55	-$1.44	+$0.11	-$1.44	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACST Acasti Pharma	N/A	N/A	N/A	N/A	N/A
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACST Acasti Pharma	N/A	7.86	7.86
CNTB Connect Biopharma	0.01	7.24	7.24
CRBP Corbus Pharmaceuticals	N/A	9.21	9.21
ZNTL Zentalis Pharmaceuticals	N/A	7.99	7.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACST Acasti Pharma	6.08%
CNTB Connect Biopharma	58.72%
CRBP Corbus Pharmaceuticals	64.64%
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ACST Acasti Pharma	13.51%
CNTB Connect Biopharma	22.60%
CRBP Corbus Pharmaceuticals	3.60%
ZNTL Zentalis Pharmaceuticals	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACST Acasti Pharma	32	9.40 million	8.77 million	Not Optionable
CNTB Connect Biopharma	110	55.72 million	43.13 million	Optionable
CRBP Corbus Pharmaceuticals	40	12.26 million	11.81 million	Optionable
ZNTL Zentalis Pharmaceuticals	160	72.14 million	70.76 million	Optionable

ACST, ZNTL, CNTB, and CRBP Headlines

Recent News About These Companies

Guggenheim Remains a Buy on Zentalis Pharmaceuticals (ZNTL)

August 19 at 7:30 AM | theglobeandmail.com

Zentalis Pharmaceuticals (ZNTL) Gets a Buy from TD Cowen

August 18 at 9:03 AM | theglobeandmail.com

Zentalis (ZNTL) Q2 Loss Narrows 70%

August 18 at 4:02 AM | theglobeandmail.com

Wedbush Issues Positive Outlook for ZNTL Earnings

August 12, 2025 | americanbankingnews.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Rating Upgraded by Wall Street Zen

August 11, 2025 | americanbankingnews.com

Leerink Partnrs Has Pessimistic View of ZNTL Q3 Earnings

August 11, 2025 | marketbeat.com

Equities Analysts Offer Predictions for ZNTL Q3 Earnings

August 11, 2025 | marketbeat.com

HC Wainwright Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to "Strong-Buy"

August 10, 2025 | marketbeat.com

Wall Street Zen Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to Hold

August 10, 2025 | marketbeat.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results

August 9, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Primecap Management Co. CA

August 9, 2025 | marketbeat.com

Zentalis price target lowered to $5 from $6 at Wells Fargo

August 8, 2025 | msn.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Cut to $5.00 by Analysts at Wells Fargo & Company

August 8, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Bought by Federated Hermes Inc.

August 7, 2025 | marketbeat.com

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

August 6, 2025 | globenewswire.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Moderate Buy" by Brokerages

August 6, 2025 | marketbeat.com

GSA Capital Partners LLP Boosts Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

August 3, 2025 | marketbeat.com

Zentalis Pharmaceuticals (ZNTL) Projected to Post Quarterly Earnings on Friday

August 1, 2025 | marketbeat.com

Decheng Capital LLC Lowers Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

July 30, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is favoured by institutional owners who hold 59% of the company

July 24, 2025 | finance.yahoo.com

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACST, ZNTL, CNTB, and CRBP Company Descriptions

Acasti Pharma NASDAQ:ACST

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Connect Biopharma NASDAQ:CNTB

$1.73 +0.06 (+3.59%)

Closing price 04:00 PM Eastern

Extended Trading

$1.70 -0.03 (-1.73%)

As of 07:51 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Corbus Pharmaceuticals NASDAQ:CRBP

$9.70 +0.48 (+5.21%)

Closing price 04:00 PM Eastern

Extended Trading

$9.53 -0.17 (-1.75%)

As of 06:49 PM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$1.87 +0.23 (+14.02%)

Closing price 04:00 PM Eastern

Extended Trading

$1.88 +0.00 (+0.27%)

As of 07:52 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time